Tuesday - November 17, 2026
Ropes and Gray: Vor Bio Expands RemGen Collaboration and Licenses Next-Generation Autoimmune Drug for Up to $356 Million
November 17, 2026
BOSTON, Massachusetts, Nov. 17 -- Ropes and Gray, a law firm, posted the following news:

* * *

Vor Bio Expands RemGen Collaboration and Licenses Next-Generation Autoimmune Drug for up to $356 Million

November 16, 2026

Ropes & Gray advised Vor Bio in an amendment to its existing agreement with China biotechnology company RemeGen for its next-generation autoimmune drug, RC298, in a deal worth up to $356 million that was announced on November . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products